VivoSeq
Oncology

Breast Cancer

2.2K

Pipeline Programs↗

1.3K

Active Trials↗

402

Companies Involved↗

Breast Cancer is a highly competitive landscape with 2172 programs across 402 companies. The most active players are Sun Pharma Advanced Research Company Limited, Jiangsu T-Mab Biopharma Co.,Ltd, Accutar Biotechnology Inc. 111 therapies are approved with 393 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

100/100

Pipeline Velocity

100/100

Mech. Concentration

2/100

Completion Rate

75/100

Attrition Rate

15/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Sun Pharma Advanced Research Company Limited logo

Sun Pharma Advanced Research Company Limited

5 programs

Phase 1J

Jiangsu T-Mab Biopharma Co.,Ltd

3 programs

Phase 1A

Accutar Biotechnology Inc

2 programs

Phase 1R

Regor Pharmaceuticals Inc.

2 programs

Phase 1R

Rovi Pharmaceuticals Laboratories

2 programs

Phase 1Relay Therapeutics logo

Relay Therapeutics

2 programs

Phase 1

Pipeline

Programs by Phase

Preclinical185

Datopotamab Deruxtecan

Daiichi Sankyo

Atezolizumab

Roche

Sacituzumab

Gilead

Eribulin Mesylate

Eisai

Methylene Blue

Provepharm SAS

Phase 1356

Alvocidib

Sumitomo Pharma America, Inc.

Incomplete Freund's Adjuvant

Eastern Cooperative Oncology Group

Paricalcitol

AbbVie

Erdafitinib

Johnson & Johnson

Ixazomib Citrate

Takeda

Phase 21127

Enfortumab Vedotin

Pfizer

Darolutamide

Bayer

Hydroxychloroquine

Alnylam Pharmaceuticals

Pemetrexed Disodium

Gynecologic Oncology Group

Aldesleukin

Iovance Biotherapeutics, Inc.

Phase 3393

Pyrotinib

Hengrui Therapeutics, Inc.

Talazoparib

Pfizer

Thiotepa

Alnylam Pharmaceuticals

Veliparib

AbbVie

Epirubicin Hydrochloride

Merck & Co.

Approved111

Osimertinib

AstraZeneca

Pemigatinib

Incyte

Exemestane

Pfizer

Tranexamic Acid

Amring

Pravastatin

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Analysis

Modality Breakdown

88%

Small molecule

2,323 of 2,642 classified programs — the dominant modality here.

12%ALL OTHERSMonoclonal antibody1586%Vaccine542%Protein / enzyme351%Cell therapy20<1%Radiopharmaceutical19<1%Antibody–drug conjugate17<1%Other16<1%

Small molecule leads; the ring shows all 2,642 classified programs, each share of the total. Modality classified for 99% of 2,829 pipeline programs.

Analysis

Trial Status

5,137

clinical trials

Completed2,367 · 46%
Unknown status685 · 13%
Recruiting614 · 12%
Terminated609 · 12%
Active, not recruiting380 · 7%
Not yet recruiting256 · 5%
Other226 · 4%

Clinical Trials

Trial Activity

5137 trials

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
Recruiting·Roche logoRoche·Phase 1/2·NCT03424005·792 enrolled
Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer
Recruiting·—·Phase 1/2·NCT05318469·34 enrolled
Study to Determine the Safety and Efficacy of Ribociclib in Combination With Hormone Therapy and Hypofractionated Radiotherapy in Breast Cancer, With Positive Hormone Receptors and Negative HER2 Status, in Newly Diagnosed, Not Immediately Operable Elderly Patient (CALHYS)
Recruiting·CCentre Antoine Lacassagne·Phase 1/2·NCT05664893·85 enrolled
Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)
Recruiting·BBeijing Biotech·Phase 1/2·NCT07486089·60 enrolled
A Real-World Study of Pyrrolitinib Maleate Tablets for HER-2-Positive Early or Locally Advanced Breast Cancer After Adjuvant Trastuzumab Therapy
Recruiting·ZZunyi Medical College·Phase 1/2·NCT06470347·67 enrolled
Study of HRS-8080 or SHR-A2009 Combined With Anti-tumor Therapy in Patients With Unresectable or Metastatic Breast Cancer
Recruiting·SShandong Suncadia Medicine Co., Ltd.·Phase 1/2·NCT06222879·350 enrolled
Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer
Recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 1/2·NCT05981014·196 enrolled
FES BPET-DBT in Newly Diagnosed Breast Cancer
Recruiting·—·Phase 1·NCT05659797·20 enrolled
Efficacy of Supplement Adjuvant Capecitabine in HR+/HER2- Breast Cancer Patients With High Risks
Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 3·NCT05212454·400 enrolled
NEODOXy: Targeting Breast Cancer Stem Cells With Doxycycline
Recruiting·SSwiss Cancer Institute·Phase 2·NCT06452394·50 enrolled
Effect of Neoadjuvant Chemotherapy on Cardiac Function of Perioperative Patients With Breast Cancer and New Strategies for Anesthesia
Recruiting·FFujian Medical University Union Hospital·Phase 4·NCT06497660·496 enrolled
Study of Zelenectide Pevedotin in Participants With Advanced Breast Cancer
Recruiting·BBicycleTx Limited·Phase 2·NCT06840483·66 enrolled
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
Recruiting·SWOG Cancer Research Network·Phase 3·NCT05929768·2,400 enrolled
Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
Recruiting·UUniversity of Washington·Phase 2·NCT06179303·60 enrolled
NEOadjuvant Abemaciclib and GIredestrant TriaL in Patients with ER-positive, HER2-negative Early Breast Cancer
Recruiting·FFondazione Oncotech·Phase 2·NCT06259929·51 enrolled
Page 1 of 343

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)